Stock Chart

KNSA

$75.79 +0.76%
Score: 64.2 HOLD
LEAPs: SELL $50
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $50
Premium: $4.10
Expiry: Dec 18, 2026
Target: $49
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.73x (vs SPY: 0.7x | vs QQQ: 0.7x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Descending Triangle weak / forming — below our quality gate quality 50/100
A Descending Triangle is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Break direction historically ~even (52% up, n=87) — scenario shown, not a forecast
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Key Statistics

Market Cap $6B
P/E Ratio 75.22

More KNSA Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This KNSA stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track KNSA's price movements with trendlines, gamma walls, and key support/resistance levels.